Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Dermatologic 3Other hematologic neoplasm 2Myeloid 1Lymphoid 1Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 208Leukemia, Lymphocytic, Chronic, B-Cell 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Hematologic Neoplasms 113Myelodysplastic Syndromes 96Leukemia 82Lymphoma 65Lymphoma, Non-Hodgkin 57Multiple Myeloma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 37Leukemia, Myelomonocytic, Chronic 35Neoplasms 31Recurrence 27Myeloproliferative Disorders 27Burkitt Lymphoma 25Lymphoma, Mantle-Cell 23Leukemia, Biphenotypic, Acute 23Lymphoma, Large B-Cell, Diffuse 22Lymphoma, Follicular 20Lymphoma, B-Cell, Marginal Zone 20Lymphoma, B-Cell 20Leukemia, Myeloid, Chronic-Phase 16Leukemia, B-Cell 16Hodgkin Disease 16Primary Myelofibrosis 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Waldenstrom Macroglobulinemia 14Hematologic Diseases 14Anemia, Refractory, with Excess of Blasts 11Neoplasm, Residual 9

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Patient Preference × Other hematologic neoplasm × Clear all
NCT06125795 2026-05-01

PROVIDENCE

AbbVie

Active not recruiting
146 enrolled
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Patient Preference

NCT05883956 2025-03-20

PREFER-HMA

Otsuka Australia Pharmaceutical Pty Ltd

Phase 3 Active not recruiting
13 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡